New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

{
  "signal_id": "816d46fc-bd5c-f6fa-356e-d0c9da9775a9",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-25T07:30:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/new-data-on-lillys-investigational-treatment-olomorasib-at-esmo-2026-show-durable-first-line-activity-in-kras-g12c-mutant-non-small-cell-lung-cancer-302918479.html",
    "title": "New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer",
    "ticker": "NYSE:LLY",
    "excerpt": "Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) across PD-L1 expression levels First-line treatment options remain an unmet need for patients with KRAS G12C-mutant NSCLC, as most patients do not receive second-line therapy due to the aggressive nature of the disease Lilly expects first randomized Phase 3 data from SUNRAY-01 in first-line KRAS G12C-mutant NSCLC in the first half of 2027 INDIANAPOLIS , Oct. 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new first-line data on olomorasib, its investigational, next-generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. Results shared in a poster presentation from the Phase 1/2 LOXO-RAS-20001 trial and the safety lead-in portion of the Phase 3 SUNRAY-01 trial of olomorasib plus Merck's anti-PD-1 therapy KEYTRUDA ® (pembrolizumab), without chemotherapy, in first-line KRAS G12C-mutant non-small cell lung cancer (NSCLC) show that median progression-free survival (PFS) and duration of response (DOR) had not been reached after a median follow-up of nearly 21 months, with durable activity observed across PD-L1 levels. Separate results in a rapid oral presentation show...",
    "product": "olomorasib",
    "summary": "Eli Lilly announced clinical trial data for its investigational KRAS G12C inhibitor olomorasib in first-line KRAS G12C-mutant non-small cell lung cancer.",
    "location": "Madrid, Spain",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS270365/ELI-LILLY-AND-COMPANY-LOGO.jpg?id=OA3036861&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "olomorasib",
      "full_text": "olomorasib, its investigational, next-generation KRAS G12C inhibitor",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-25T07:30:00Z",
    "location_data": [
      {
        "city": "Madrid",
        "state": "Community of Madrid",
        "region": "Southern Europe",
        "country": "Spain",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-25",
    "article_sentence": "INDIANAPOLIS , Oct. 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new first-line data on olomorasib, its investigational, next-generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain."
  }
}

curl https://signals.autobound.ai/v1/signals/816d46fc-bd5c-f6fa-356e-d0c9da9775a9 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'